What is the address of PHARMA JUMP CONSULTING?

The registered office of PHARMA JUMP CONSULTING is located at Avenue des Pâquerettes 2 box A, 4000 Liège.

Is PHARMA JUMP CONSULTING still active?

Yes. According to the CBE (29 October 2026) PHARMA JUMP CONSULTING is active, legal situation “Normale toestand”, started on 24 January 2018.

Is PHARMA JUMP CONSULTING registered on Peppol?

Yes, PHARMA JUMP CONSULTING is registered on the Peppol network with ID 0208:0688827286.

What is the enterprise number of PHARMA JUMP CONSULTING?

The enterprise number of PHARMA JUMP CONSULTING is BE0688827286.

When was PHARMA JUMP CONSULTING founded?

PHARMA JUMP CONSULTING was founded on 24 January 2018.

Who are the directors of PHARMA JUMP CONSULTING?

According to the 2025 annual accounts, the directors of PHARMA JUMP CONSULTING are: LAURENCE BOURGARD, Patrick JEUKENNE.

Is PHARMA JUMP CONSULTING a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 24 January 2018; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMA JUMP CONSULTING make in 2025?

PHARMA JUMP CONSULTING recorded a loss after taxes of € 12,934 in financial year 2025.

What is the revenue of PHARMA JUMP CONSULTING?

As a small company, PHARMA JUMP CONSULTING is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -2,780.

PHARMA JUMP CONSULTING (Private Limited) - Liège

Q: What does PHARMA JUMP CONSULTING do?

PHARMA JUMP CONSULTING is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 24 January 2018, 1 establishment.

Dossier PHARMA JUMP CONSULTING, printed on 29 October 2026 from databakkes.be/en/0688827286/pharma-jump-consulting. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 1 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

PHARMA JUMP CONSULTING from Liège, company number BE0688827286, closed financial year 2025 with a result of € -12,934 after tax. For that financial year PHARMA JUMP CONSULTING recorded a gross margin of € -2,780 and equity of € -7,761. Compared with financial year 2024, the result moved from € -13,427 to € -12,934. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.

What it is worth Caution

€ -7,761

▼ € 12,934 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -12,934

▲ 4 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 3,298

▼ 88% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -26,361.

People and assets in 2025

Vehicles and equipment

€ 9,397

▼ 49% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 19,340

▲ € 14,725 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 12,102

▼ 36% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 6,074 Gross margin 2022: € 6,074 First fiscal year in the series	€ 63,549 Gross margin 2023: € 63,549 ▲ € 57,475 vs 2022 (€ 6,074) Favourable step	€ -3,589 Gross margin 2024: € -3,589 ▼ € 67,138 vs 2023 (€ 63,549) Unfavourable step	€ -2,780 Gross margin 2025: € -2,780 ▲ € 809 vs 2024 (€ -3,589) Favourable step	▲ € 809
Profit after taxes	€ 2,681 Profit after taxes 2022: € 2,681 First fiscal year in the series	€ 42,993 Profit after taxes 2023: € 42,993 ▲ € 40,312 vs 2022 (€ 2,681) Favourable step	€ -13,427 Profit after taxes 2024: € -13,427 ▼ € 56,420 vs 2023 (€ 42,993) Unfavourable step	€ -12,934 Profit after taxes 2025: € -12,934 ▲ € 492 vs 2024 (€ -13,427) Favourable step	▲ € 492
Equity	€ 38,478 Equity 2022: € 38,478 First fiscal year in the series	€ 18,600 Equity 2023: € 18,600 ▼ 52% vs 2022 (€ 38,478) Unfavourable step	€ 5,173 Equity 2024: € 5,173 ▼ 72% vs 2023 (€ 18,600) Unfavourable step	€ -7,761 Equity 2025: € -7,761 ▼ € 12,934 vs 2024 (€ 5,173) Unfavourable step	▼ € 12,934
Total debts	€ 13,645 Total debts 2022: € 13,645 First fiscal year in the series	€ 84,484 Total debts 2023: € 84,484 ▲ € 70,838 vs 2022 (€ 13,645) Unfavourable step	€ 71,042 Total debts 2024: € 71,042 ▼ 16% vs 2023 (€ 84,484) Favourable step	€ 74,735 Total debts 2025: € 74,735 ▲ 5% vs 2024 (€ 71,042) Unfavourable step	▲ 5%
Cash	€ 19,643 Cash 2022: € 19,643 First fiscal year in the series	€ 55,483 Cash 2023: € 55,483 ▲ 182% vs 2022 (€ 19,643) Favourable step	€ 27,748 Cash 2024: € 27,748 ▼ 50% vs 2023 (€ 55,483) Unfavourable step	€ 3,298 Cash 2025: € 3,298 ▼ 88% vs 2024 (€ 27,748) Unfavourable step	▼ 88%
Retained profit	€ 19,878 Retained profit 2022: € 19,878 First fiscal year in the series	€ 0 Retained profit 2023: € 0 ▼ 100% vs 2022 (€ 19,878) Unfavourable step	€ -13,427 Retained profit 2024: € -13,427 Unchanged (€ 0) Unfavourable step	€ -26,361 Retained profit 2025: € -26,361 ▼ € 12,934 vs 2024 (€ -13,427) Unfavourable step	▼ € 12,934
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 62,871 Dividend 2023: € 62,871 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 62,871) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 52,123 Balance sheet total 2022: € 52,123 First fiscal year in the series	€ 103,084 Balance sheet total 2023: € 103,084 ▲ 98% vs 2022 (€ 52,123) Unchanged	€ 76,215 Balance sheet total 2024: € 76,215 ▼ 26% vs 2023 (€ 103,084) Unchanged	€ 66,973 Balance sheet total 2025: € 66,973 ▼ 12% vs 2024 (€ 76,215) Unchanged	▼ 12%

Key figures of PHARMA JUMP CONSULTING, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA JUMP CONSULTING?

What happened at PHARMA JUMP CONSULTING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 29, 2026 New annual accounts for financial year 2025: loss of € 12,934. Source: NBB ↗
Jan 24, 2018 New establishment in Liège. KBO
Jan 24, 2018 Start of the company according to the CBE. KBO

In short

From € 2,681 profit in 2022 to € 12,934 loss in 2025.

Paid € 13,536 in corporate taxes since 2022.

Best year ever: 2023, with € 42,993 profit.

Paid out € 62,871 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

LAURENCE BOURGARD Patrick JEUKENNE

PHARMA JUMP CONSULTING

Behind PHARMA JUMP CONSULTING are LAURENCE BOURGARD and Patrick JEUKENNE.

Directors

According to the 2025 annual accounts

LAURENCE BOURGARD

Director

Patrick JEUKENNE

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Avenue des Pâquerettes 2 box A

4000 Liège

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0688.827.286

VAT number

BE 0688.827.286

Registered office

Avenue des Pâquerettes 2 bus A, 4000 Liège

Names & denominations

PHARMA JUMP CONSULTING

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

24 January 2018

Peppol

Active · Active since 24 Dec 2025

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren

Overige vormen van onderwijs

Activiteiten van reclamebureaus

Vervaardiging van farmaceutische grondstoffen

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA JUMP CONSULTING

Warning lights

Financials

What happened to PHARMA JUMP CONSULTING?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions